One might surmise that by the time FDA asks an advisory committee to vet an application, the questions would deal primarily with clinical utility.
New research led by Friends of Cancer Research demonstrates that decreases in circulating tumor DNA after initiation of treatment are associated with improved overall survival in patients with advanced non-small cell lung cancer treated with immunotherapy or chemotherapy.
